Global Opioid-Induced Constipation market will register a 4.4% CAGR in terms of revenue, the market size will reach USD 2.77 Billion by 2024, from USD 2.24 Billion in 2019.
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
In the last several years, global market of Opioid-Induced Constipation developed smoothly, with an average growth rate of 3.85% from the forecast period 2019 to 2025.
The classification of Opioid-Induced Constipation includes Methylnaltrexone Bromide, Lubiprostone, Naloxegol and other OTC drugs. The revenue proportion of Lubiprostone in 2017 is about 33%, and the proportion of OTC drugs is in about 34%.
Opioid-Induced Constipation is widely sold in Hospital, Pharmacy and other field. The most proportion of Opioid-Induced Constipation is sold in Pharmacy, and the proportion in 2017 is 45.99%.
According to this study, over the next five years the Opioid-Induced Constipation market will register a 4.4% CAGR in terms of revenue, the global market size will reach US$ 2770 million by 2024, from US$ 2240 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Opioid-Induced Constipation business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioid-Induced Constipation market by product type, application, key manufacturers and key regions and countries.
This study considers the Opioid-Induced Constipation value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Pharmacy
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Opioid-Induced Constipation consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Opioid-Induced Constipation market by identifying its various subsegments.
Focuses on the key global Opioid-Induced Constipation manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Opioid-Induced Constipation with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Opioid-Induced Constipation submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hrs) post payment.
Table of Contents
2019-2024 Global Opioid-Induced Constipation Consumption 麻豆原创 Report
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 麻豆原创 Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Opioid-Induced Constipation Consumption 2014-2024
2.1.2 Opioid-Induced Constipation Consumption CAGR by Region
2.2 Opioid-Induced Constipation Segment by Type
2.2.1 Methylnaltrexone Bromide
2.2.2 Lubiprostone
2.2.3 Naloxegol
2.2.4 Others
2.3 Opioid-Induced Constipation Consumption by Type
2.3.1 Global Opioid-Induced Constipation Consumption 麻豆原创 Share by Type (2014-2019)
2.3.2 Global Opioid-Induced Constipation Revenue and 麻豆原创 Share by Type (2014-2019)
2.3.3 Global Opioid-Induced Constipation Sale Price by Type (2014-2019)
2.4 Opioid-Induced Constipation Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.5 Opioid-Induced Constipation Consumption by Application
2.5.1 Global Opioid-Induced Constipation Consumption 麻豆原创 Share by Application (2014-2019)
2.5.2 Global Opioid-Induced Constipation Value and 麻豆原创 Share by Application (2014-2019)
2.5.3 Global Opioid-Induced Constipation Sale Price by Application (2014-2019)
3 Global Opioid-Induced Constipation by Players
3.1 Global Opioid-Induced Constipation Sales 麻豆原创 Share by Players
3.1.1 Global Opioid-Induced Constipation Sales by Players (2017-2019)
3.1.2 Global Opioid-Induced Constipation Sales 麻豆原创 Share by Players (2017-2019)
3.2 Global Opioid-Induced Constipation Revenue 麻豆原创 Share by Players
3.2.1 Global Opioid-Induced Constipation Revenue by Players (2017-2019)
3.2.2 Global Opioid-Induced Constipation Revenue 麻豆原创 Share by Players (2017-2019)
3.3 Global Opioid-Induced Constipation Sale Price by Players
3.4 Global Opioid-Induced Constipation Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Opioid-Induced Constipation Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Opioid-Induced Constipation Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Opioid-Induced Constipation by Regions
4.1 Opioid-Induced Constipation by Regions
4.1.1 Global Opioid-Induced Constipation Consumption by Regions
4.1.2 Global Opioid-Induced Constipation Value by Regions
4.2 Americas Opioid-Induced Constipation Consumption Growth
4.3 APAC Opioid-Induced Constipation Consumption Growth
4.4 Europe Opioid-Induced Constipation Consumption Growth
4.5 Middle East & Africa Opioid-Induced Constipation Consumption Growth
5 Americas
5.1 Americas Opioid-Induced Constipation Consumption by Countries
5.1.1 Americas Opioid-Induced Constipation Consumption by Countries (2014-2019)
5.1.2 Americas Opioid-Induced Constipation Value by Countries (2014-2019)
5.2 Americas Opioid-Induced Constipation Consumption by Type
5.3 Americas Opioid-Induced Constipation Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Opioid-Induced Constipation Consumption by Countries
6.1.1 APAC Opioid-Induced Constipation Consumption by Countries (2014-2019)
6.1.2 APAC Opioid-Induced Constipation Value by Countries (2014-2019)
6.2 APAC Opioid-Induced Constipation Consumption by Type
6.3 APAC Opioid-Induced Constipation Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries
7 Europe
7.1 Europe Opioid-Induced Constipation by Countries
7.1.1 Europe Opioid-Induced Constipation Consumption by Countries (2014-2019)
7.1.2 Europe Opioid-Induced Constipation Value by Countries (2014-2019)
7.2 Europe Opioid-Induced Constipation Consumption by Type
7.3 Europe Opioid-Induced Constipation Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Opioid-Induced Constipation by Countries
8.1.1 Middle East & Africa Opioid-Induced Constipation Consumption by Countries (2014-2019)
8.1.2 Middle East & Africa Opioid-Induced Constipation Value by Countries (2014-2019)
8.2 Middle East & Africa Opioid-Induced Constipation Consumption by Type
8.3 Middle East & Africa Opioid-Induced Constipation Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 麻豆原创 Challenges and Impact
9.3 麻豆原创 Trends
10 麻豆原创ing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Opioid-Induced Constipation Distributors
10.3 Opioid-Induced Constipation Customer
11 Global Opioid-Induced Constipation 麻豆原创 Forecast
11.1 Global Opioid-Induced Constipation Consumption Forecast (2019-2024)
11.2 Global Opioid-Induced Constipation Forecast by Regions
11.2.1 Global Opioid-Induced Constipation Forecast by Regions (2019-2024)
11.2.2 Global Opioid-Induced Constipation Value Forecast by Regions (2019-2024)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States 麻豆原创 Forecast
11.3.2 Canada 麻豆原创 Forecast
11.3.3 Mexico 麻豆原创 Forecast
11.3.4 Brazil 麻豆原创 Forecast
11.4 APAC Forecast by Countries
11.4.1 China 麻豆原创 Forecast
11.4.2 Japan 麻豆原创 Forecast
11.4.3 Korea 麻豆原创 Forecast
11.4.4 Southeast Asia 麻豆原创 Forecast
11.4.5 India 麻豆原创 Forecast
11.4.6 Australia 麻豆原创 Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany 麻豆原创 Forecast
11.5.2 France 麻豆原创 Forecast
11.5.3 UK 麻豆原创 Forecast
11.5.4 Italy 麻豆原创 Forecast
11.5.5 Russia 麻豆原创 Forecast
11.5.6 Spain 麻豆原创 Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt 麻豆原创 Forecast
11.6.2 South Africa 麻豆原创 Forecast
11.6.3 Israel 麻豆原创 Forecast
11.6.4 Turkey 麻豆原创 Forecast
11.6.5 GCC Countries 麻豆原创 Forecast
11.7 Global Opioid-Induced Constipation Forecast by Type
11.8 Global Opioid-Induced Constipation Forecast by Application
12 Key Players Analysis
12.1 Takeda Pharmaceuticals
12.1.1 Company Details
12.1.2 Opioid-Induced Constipation Product Offered
12.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
12.1.4 Main Business Overview
12.1.5 Takeda Pharmaceuticals News
12.2 Bayer
12.2.1 Company Details
12.2.2 Opioid-Induced Constipation Product Offered
12.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
12.2.4 Main Business Overview
12.2.5 Bayer News
12.3 Sanofi
12.3.1 Company Details
12.3.2 Opioid-Induced Constipation Product Offered
12.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
12.3.4 Main Business Overview
12.3.5 Sanofi News
12.4 Mallinckrodt
12.4.1 Company Details
12.4.2 Opioid-Induced Constipation Product Offered
12.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
12.4.4 Main Business Overview
12.4.5 Mallinckrodt News
12.5 Salix (Bausch Health)
12.5.1 Company Details
12.5.2 Opioid-Induced Constipation Product Offered
12.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
12.5.4 Main Business Overview
12.5.5 Salix (Bausch Health) News
12.6 AstraZeneca
12.6.1 Company Details
12.6.2 Opioid-Induced Constipation Product Offered
12.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
12.6.4 Main Business Overview
12.6.5 AstraZeneca News
12.7 Progenics Pharmaceuticals
12.7.1 Company Details
12.7.2 Opioid-Induced Constipation Product Offered
12.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
12.7.4 Main Business Overview
12.7.5 Progenics Pharmaceuticals News
12.8 Purdue Pharm
12.8.1 Company Details
12.8.2 Opioid-Induced Constipation Product Offered
12.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
12.8.4 Main Business Overview
12.8.5 Purdue Pharm News
12.9 Nektar Therapeutics
12.9.1 Company Details
12.9.2 Opioid-Induced Constipation Product Offered
12.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
12.9.4 Main Business Overview
12.9.5 Nektar Therapeutics News
12.10 Daiichi Sankyo
12.10.1 Company Details
12.10.2 Opioid-Induced Constipation Product Offered
12.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
12.10.4 Main Business Overview
12.10.5 Daiichi Sankyo News
12.11 Prestige
12.12 GSK
12.13 Shionogi
13 Research Findings and Conclusion
听
听
*If Applicable.